XpresSpa Extends Partnership With CDC For Biosurveillance At US Airports

XpresSpa Group Inc XSPA has extended its initial $2 million airport-based biosurveillance program with the Centers for Disease Control and Prevention (CDC) through its subsidiary XpresCheck. The extension brings the total contract to $5.6 million.
The COVID-19 biosurveillance program, first launched in September 2021, provided testing for travelers arriving from India at three key U.S. airports, including John F. Kennedy International Airport, Newark-Liberty International Airport, and San Francisco International Airport.
With the recent expansion, the program now tests passengers entering the U.S. from seven African countries, including passengers making connections through the U.K., France, Germany, and Brazil.
The expansion includes the addition of Hartsfield-Jackson Atlanta International Airport, bringing the number of testing sites to four.
Price Action: XSPA shares traded higher by 4.10% at $1.40 on the last check Monday.